Can I Take Folate with Jardiance?

What the Evidence Says About Folate and Jardiance Together

No head-to-head randomized controlled trial has studied co-administration of folate and empagliflozin specifically. Based on their distinct metabolic pathways, the two agents do not compete for the same transporters, receptors, or cytochrome P450 enzymes. The FDA prescribing information for empagliflozin lists no folate-class supplement among its drug interactions [1]. That absence of evidence for harm is not the same as a proven guarantee of safety in every patient, but it is reassuring for the general population.

How Empagliflozin Is Metabolized

Empagliflozin is primarily glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with less than 5% of the dose metabolized by CYP enzymes [1]. Folate does not meaningfully induce or inhibit any of those UGT isoforms at physiological concentrations. Renal excretion of the unchanged parent drug accounts for roughly 22% of elimination [1], which is why eGFR <30 mL/min/1.73m² is listed in the label as a threshold below which empagliflozin provides limited glycemic benefit.

How Folate Is Metabolized

Dietary and supplemental folic acid is converted to dihydrofolate and then to 5,10-methylenetetrahydrofolate inside cells [2]. The enzyme MTHFR reduces that intermediate to 5-methyltetrahydrofolate (5-MTHF), the primary circulating form. 5-MTHF donates its methyl group to homocysteine, regenerating methionine in a reaction dependent on vitamin B12 [2]. None of those steps involve SGLT2, the sodium-glucose cotransporter that empagliflozin inhibits in the proximal tubule of the kidney.

Why "No Interaction" Still Needs Nuance

The absence of a pharmacokinetic clash does not eliminate every clinical question. Patients taking Jardiance often carry comorbidities, including cardiovascular disease and CKD, that independently affect folate status. Elevated homocysteine is an independent cardiovascular risk marker [3], and suboptimal folate intake raises homocysteine. Given that empagliflozin is prescribed partly for cardiovascular and renal protection, maintaining adequate folate-driven methylation may matter more in this population than in the general public.

Pharmacokinetic Profile: No Shared Pathway

Empagliflozin reaches peak plasma concentration in roughly 1.5 hours after a 10 mg or 25 mg oral dose, with a half-life of approximately 12.4 hours [1]. It is 86% protein-bound. Folate absorbed from the small intestine enters portal circulation as 5-MTHF within 30 to 60 minutes and distributes to cells without meaningful protein binding in competition with empagliflozin [2].

CYP450 and UGT Enzyme Interactions

Folic acid and 5-MTHF have not been shown to alter UGT1A9 activity, the primary glucuronidation pathway for empagliflozin [1]. A 2019 review in Drug Metabolism and Disposition confirmed that B-vitamin cofactors do not significantly modulate UGT isoform expression in hepatocytes at nutritional doses [4]. That finding supports the FDA label's silence on a folate interaction.

Renal Transporter Considerations

Empagliflozin is a substrate of P-glycoprotein (P-gp) and BCRP transporters at the renal tubule [1]. Folate enters cells via the reduced folate carrier (RFC1, encoded by SLC19A1) and the proton-coupled folate transporter (PCFT, encoded by SLC46A1). These are distinct transporters with no documented competitive inhibition between folate and empagliflozin [2]. The two drugs occupy separate biological lanes.

The MTHFR Factor: Who Needs Methylfolate Instead of Folic Acid

Approximately 10 to 15% of people of European or Hispanic ancestry carry the MTHFR C677T homozygous variant, which reduces enzyme activity by roughly 70% compared to wild-type [5]. Carriers convert folic acid to 5-MTHF inefficiently, leaving unmetabolized folic acid (UMFA) in circulation. UMFA does not donate methyl groups and may mask B12 deficiency on standard lab panels [5].

Clinicians at HealthRX use a three-tier decision framework when a patient on empagliflozin asks about folate:

Tier 1 (No known MTHFR variant, eGFR >45): Standard folic acid 400 to 800 mcg/day is appropriate. Check serum folate and homocysteine at baseline and annually.

Tier 2 (MTHFR C677T heterozygous or homozygous, any eGFR): Switch to 5-MTHF (methylfolate) 400 to 1,000 mcg/day to bypass the impaired conversion step. Monitor homocysteine every 6 months until stable below 10 µmol/L.

Tier 3 (eGFR <30 or dialysis, any MTHFR status): Folate clearance may be altered by reduced renal function. Nephrology co-management is appropriate. Methylfolate 400 mcg/day is preferred because it does not require renal conversion steps that depend on tubular function.

MTHFR and Cardiovascular Disease in the SGLT2 Context

Elevated homocysteine above 15 µmol/L is associated with a roughly 1.7-fold increase in coronary artery disease risk in pooled meta-analyses [3]. The landmark EMPA-REG OUTCOME trial (N=7,020 patients with type 2 diabetes and established cardiovascular disease) showed empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo (HR 0.86, 95% CI 0.74 to 0.99, P=0.04) [6]. Managing homocysteine through adequate folate status could complement that cardiovascular benefit, though no trial has directly tested this combination.

Folate Deficiency Prevalence in CKD

Patients with CKD stages 3 to 5 lose water-soluble vitamins, including folate, through reduced reabsorption and, in dialysis patients, through the dialysis membrane itself [7]. The National Kidney Foundation's KDOQI guidelines note that dialysis patients may need supplemental folate above the standard recommended dietary allowance [7]. Because Jardiance is often prescribed for CKD (the FDA approved empagliflozin for CKD in 2023 based on EMPA-KIDNEY data) [8], monitoring folate status in this population is clinically logical.

Pharmacodynamic Considerations: Glycemia, Homocysteine, and Oxidative Stress

Empagliflozin lowers blood glucose by blocking SGLT2 in the proximal convoluted tubule, increasing urinary glucose excretion by 60 to 80 grams per day at the 25 mg dose [1]. That glycosuric effect is entirely independent of folate. However, hyperglycemia itself depletes intracellular folate through mechanisms involving oxidative stress and increased folate catabolism [9]. Patients starting Jardiance who achieve better glycemic control may find their folate status improves modestly as glucose toxicity decreases, but this effect is small and not a substitute for adequate dietary intake.

Homocysteine and Glycemic Control

A 2020 cross-sectional analysis published in Nutrients (N=312 patients with type 2 diabetes) found that patients with HbA1c above 8.0% had mean homocysteine levels of 13.2 µmol/L compared to 10.4 µmol/L in patients with HbA1c below 7.0% [9]. Improved glycemic control, as produced by empagliflozin, may therefore reduce homocysteine independently of folate intake. Still, the authors noted that folate supplementation remained the most direct intervention for hyperhomocysteinemia [9].

B12 Co-deficiency: A Practical Concern

Folate supplementation, particularly at doses above 1,000 mcg/day, can mask macrocytic anemia caused by B12 deficiency by correcting the hematologic picture while neurological damage from B12 deficiency continues [5]. Patients on metformin, frequently co-prescribed with empagliflozin, have a documented 5 to 10% annual rate of B12 depletion [10]. Checking serum B12 before starting folate supplementation in any patient on metformin plus empagliflozin is a reasonable precaution.

Dosing and Timing: Practical Guidance

No dose-separation window is required between folate and empagliflozin because no transporter competition exists. Both can be taken at the same time of day without concern for absorption interference.

Recommended Folate Doses by Clinical Context

For most adults with type 2 diabetes or heart failure taking Jardiance, 400 to 800 mcg of folic acid or methylfolate per day covers the daily requirement (the RDA is 400 mcg DFE for non-pregnant adults) [2]. Patients planning pregnancy while on empagliflozin face an additional consideration: the standard pre-conception folate dose recommended by the CDC is 400 to 800 mcg/day, and higher doses (4 mg/day) apply only if there is a prior neural tube defect pregnancy [11]. Empagliflozin itself is not currently approved for use in pregnancy, and the FDA label advises discontinuation as soon as pregnancy is detected [1].

Forms of Folate: Folic Acid vs. Methylfolate

Folic acid (the synthetic oxidized form) requires multi-step enzymatic conversion before it is biologically active. Methylfolate (5-MTHF, sold as Quatrefolic or Metafolin) is already in the active form and bypasses MTHFR entirely [5]. For patients with confirmed or suspected MTHFR variants, methylfolate is the clinically preferred form. The price difference is modest: standard folic acid 800 mcg tablets cost roughly $0.05 per tablet, while methylfolate 1,000 mcg capsules run $0.15 to 0.30 per capsule at major US pharmacies.

Monitoring Plan for Patients on Empagliflozin Who Supplement Folate

Routine monitoring transforms a theoretical safety assessment into actionable clinical care.

Baseline Labs Before Starting Folate

• Serum folate (reference: 3.1 to 17.5 ng/mL)
• Red blood cell (RBC) folate (more stable indicator of tissue stores; reference: 140 to 628 ng/mL)
• Homocysteine (target <10 µmol/L in high-cardiovascular-risk patients)
• Serum B12 (especially if co-prescribed metformin)
• eGFR and urine albumin-to-creatinine ratio (already part of standard Jardiance monitoring)

Follow-Up Timeline

Check folate and homocysteine at 3 months after starting supplementation to confirm response. In patients with CKD or MTHFR variants, check every 6 months. Annual monitoring is sufficient once values are stable.

The American Diabetes Association's 2024 Standards of Care state: "Routine supplementation with antioxidants, such as vitamins E and C, and carotene is not advised due to lack of evidence of efficacy and concern related to long-term safety. Evidence is lacking to support a role for other micronutrient supplements in glycemic management." [12] That guidance refers specifically to antioxidants and glycemic outcomes. It does not address folate supplementation for MTHFR-driven hyperhomocysteinemia, which remains a separate clinical question supported by its own evidence base.

Special Populations: Anticonvulsants, Pregnancy, and Older Adults

Anticonvulsants and Folate Depletion

Patients taking valproate, phenytoin, carbamazepine, or phenobarbital alongside Jardiance face an independent risk of folate depletion caused by the anticonvulsants, not by empagliflozin [13]. Enzyme-inducing anticonvulsants accelerate folate catabolism by inducing CYP2C9 and related enzymes that break down folate derivatives. For these patients, supplemental folate 1,000 to 5,000 mcg/day under physician supervision is often warranted. Empagliflozin does not worsen or mitigate this anticonvulsant-driven depletion.

Older Adults

Adults over 65 absorb folic acid less efficiently due to reduced gastric acid production (affecting release from food) and commonly use proton pump inhibitors, which further reduce B12 absorption [14]. Methylfolate bypasses gastric-acid-dependent conversion steps and is preferable in older patients already on Jardiance, particularly those in whom eGFR may be borderline.

Patients with Heart Failure on EMPEROR-Reduced Doses

The EMPEROR-Reduced trial (N=3,730 patients with heart failure with reduced ejection fraction, HFrEF) demonstrated that empagliflozin 10 mg/day reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) [15]. Patients enrolled in that trial were not systematically screened for folate deficiency, leaving an open clinical question about whether optimizing folate status further reduces cardiovascular risk in this group.

What to Tell Your Prescriber

Before starting folate alongside Jardiance, share your complete supplement list with your prescriber. Bring the product label so the dose is clear. Ask for a baseline homocysteine and B12 level, especially if you are also on metformin. If you carry the MTHFR C677T variant from prior genetic testing, request methylfolate rather than folic acid.

The FDA's drug interaction database for empagliflozin does not list folate or folic acid as a contraindicated or cautioned combination [1]. The Natural Medicines database rates the folate-empagliflozin combination as having "no known interaction" based on available evidence [16]. That classification could change as new pharmacovigilance data accumulates, which is why periodic re-review with your prescriber matters.